D. Alec Lindley, MD; Charles J. Schleupner, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: Pentamidine is commonly used to treat patients with Pneumocystis carinii pneumonia. Although often effective, the drug is frequently associated with adverse effects when administered parenterally. These effects include an elevation of transaminase levels, nausea, vomiting, hypoglycemia, azotemia, anemia, fever, and leukopenia; pain at the injection site or sterile abscess formation can occur when the drug is given intramuscularly (1). The incidence of these side effects has ranged from 50% to 83% (1, 2). Aerosolized pentamidine therapy has been found efficacious in less severe cases of P. carinii pneumonia, and significantly fewer adverse effects have been reported (2,
Lindley DA, Schleupner CJ. Aerosolized Pentamidine and Conjunctivitis. Ann Intern Med. ;109:988. doi: 10.7326/0003-4819-109-12-988_1
Download citation file:
Published: Ann Intern Med. 1988;109(12):988.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use